drugset
drugset / Trial / NCT07071090

A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

NCT07071090 ↗

Phase 1 Recruiting 32 enrolled Heronova Pharmaceuticals
NaSequentialOpen-labelTreatment

Summary

This study employs a non-randomized, open-label design to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of DC50292A tablets in patients with MTAP-deficient advanced or metastatic solid tumors. The study consists of two parts: dose escalation and dose expansion.

Timeline

Start
2025-06-30
Primary completion
2028-01-01
Completion
2028-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject DC50292A Unknown 40 mg Oral
Subject DC50292A Unknown 100 mg Oral
Subject DC50292A Unknown 200 mg Oral
Subject DC50292A Unknown 400 mg Oral
Subject DC50292A Unknown 600 mg Oral
Subject DC50292A Unknown 900 mg Oral

Indications

No indication recorded.